NCT01721759

Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens

A Single-Arm Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 117 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to assess the objective response rate (change in tumor size from baseline) in patients with advanced or metastatic squamous cell nonsmall-cell lung cancer treated with Nivolumab (BMS-936558) after failure of 2 prior systemic regimens

Conditions

• Squamous Cell Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Nivolumab

Timeline

• Start date: 2012-11-16
• Primary completion: 2014-01-22
• Completion: 2021-04-22
• First posted: 2012-11-06
• Last updated: 2022-06-28
• Results posted: 2015-10-22

Locations

33 sites across 4 countries: United States, France, Germany, Italy

Regulatory

• FDA-regulated drug study